A few companies are in clinicals with novel approaches to heal an initial brain injury or minimize secondary damage. Slow progress may be more related to investors’ misperceptions of the topic than ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, psychosocial, and physiological perspective, according to dermatologists who spoke at ...

AI was a key theme at OCT Medical Devices 2025, yet human sensibility appears to be the true differentiator in clinical trial success.

It is intended to supplement established first choice reporting tools, such as Consolidated Standards of Reporting Trials (CONSORT), by adding tacit ... in the trial planning phase, ensured that the ...

Future directions for ctDNA in the preoperative setting involve assaying circulating or urinary cell-free DNA through NGS after UTUC diagnosis. This approach aims to improve accurate staging and ...

Enrollment Performance Two Segal Trials investigators, Rishi Kakar, MD and Olga Lapeyra, MD, accounted for 18% of the total sample size in the Phase 2 study. A consistent top-enroller in acute ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Singh confirmed that the PALISADE-3 and PALISADE-4 Phase 3 trials are advancing, with top-line results expected later in 2025. He emphasized the absence of an FDA-approved medication for this ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad ...

let's take a moment to orient ourselves in the moon phases diagram below, beginning with imagining Earth at the center of this illustration and the sun adjacent to the new moon. Think of the ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).